AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00923845
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclosporine: 2 mg/kg every 12 hours PO or IV starting on day -4 of hematopoietic stem cell transplant (HSCT)
Trial: NCT03546088
Drug: Topical anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anaesthesia with lidocaine will be provided through nebulisation and instillation. The intubating tube will be lubricated with a gel containing lidocaine.
Trial: NCT01810315
Drug: TFV 1% gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03851055
Drug: Zinc
RxNorm normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One arm will receive Zinc Second arm will receive placebo
Trial: NCT00559988
Drug: Physician-Directed OAC
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive physician-directed anticoagulation therapy based on conventional criteria.~OAC drugs used: Dabigatran etexilate, Rivaroxaban, Warfarin, other approved VKA
Trial: NCT02678923
Drug: MDCO-216
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02678923
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00311259
Drug: Melatonin (drug)
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00914329
Drug: Gelsemium Sempervirens
RxNorm normalized name: Gelsemium sempervirens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5CH, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.
Trial: NCT00914329
Drug: Gelsemium Sempervirens
RxNorm normalized name: Gelsemium sempervirens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15CH, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.
Trial: NCT00914329
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.
Trial: NCT01046539
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg
Trial: NCT02437487
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be identical to the investigator product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline.
Trial: NCT00311259
Drug: Laktose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02727491
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo syrup identical to active comparator in taste, appearance and volume but is inactive. Placebo comparator will be used in the placebo arm of the trial.
Trial: NCT01803308
Drug: SB9200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part B randomised 6:2 (active:placebo) using recommended Part B starting dose, and ascending to up to 1500mg for 7-14 days of dosing.
Trial: NCT01803308
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part B randomised 6:2 (active:placebo) using anhydrous lactose capsules identical to active comparator, minus active ingredient.
Trial: NCT02638948
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of BMS-986142 specific dose on specific days
Trial: NCT02638948
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate specific dose on specific days
Trial: NCT03085485
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo pills
Trial: NCT02036489
Drug: Ciclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02036489
Drug: Metotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00488995
Drug: CP-675,206
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02036489
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02382198
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01299948
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg prednisolone orally per day
Trial: NCT00951275
Drug: Standard DMARDs (Disease Modifying Anti Rheumatic Drugs)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed
Trial: NCT01536132
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (same appearance than active drug) is administered with the same dosing regime
Trial: NCT04616261
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhalation of placebo
Trial: NCT00803452
Drug: doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral doxycycline 100mg bid
Trial: NCT00803452
Drug: azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: topical 1% azithromycin daily to eye
Trial: NCT01183065
Drug: Pralatrexate With Vitamin B12 and Folic Acid
RxNorm normalized name: VITAMIN B12 AND FOLIC ACID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated with 30 mg/m2 of pralatrexate intravenously once weekly for 3 weeks in a 4 week cycle with vitamin supplementation. Patients will take 1.0-1.25 mg oral folic acid on a daily basis. Folic acid should be initiated during the 10-day period preceding the first dose of pralatrexate and dosing will be continued during the full course of therapy and for 30 days after the last dose of pralatrexate. Patients will also receive a vitamin B12 (1 mg) intramuscular injection no more than 10 weeks prior to the first dose of pralatrexate and every 8-10 weeks thereafter. Subsequent vitamin B12 injections may be given the same day as treatment with pralatrexate.
Trial: NCT00416455
Drug: ferumoxtran-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undergo femoxtran-10 MRI
Trial: NCT02280317
Drug: VAL201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAL201-001 Sub-cutaneous injection.
Trial: NCT02073019
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04534881
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized to receive generic micronized progesterone 200 mg or placebo tablets, to be taken at bedtime daily.
Trial: NCT02386826
Drug: INC280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Escalation: INC280 by mouth (PO) twice daily for 28 days according to the following schedule until the maximum tolerated dose (MTD) is determined:~Dose Level 1 (starting dose): 200 mg (divided dose of 100 mg twice per day) Dose Level 2: 400 mg (divided dose of 200 mg twice per day) Dose Level 3: 800 mg (divided dose of 400 mg twice per day)~Dose Expansion: INC280 PO twice daily at the MTD determined in the dose escalation phase
Trial: NCT00737555
Drug: CHR-2797
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral once daily administration of capsules of CHR-2797, to determine safety and tolerability in patients being treated with paclitaxel infusion every 3 weeks for up to 18 weeks.
Trial: NCT00363519
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-blind period (12 wk); placebo QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
Trial: NCT01005056
Drug: Ethinylestradiol + Desogestrel
RxNorm normalized name: desogestrel and ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants receive Marvelon® according to the approved dosage and administration method.
Trial: NCT03927911
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care
Trial: NCT00842140
Drug: Oral contraceptive plus spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patient will receive an oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 100 mg spironolactone. One pill each once a day for twelve months.
Trial: NCT01257906
Drug: CLIND PHOSPHATE (1.2%) AND TRETINOIN (0.025%) TOPICAL GEL
RxNorm normalized name: clindamycin phosphate / tretinoin Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Gel applied in the evening for 84 days
Trial: NCT01257906
Drug: ZIANA®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Gel applied in the evening for 84 days
Trial: NCT04365582
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg day 1 ; 250 mg/day for 4 days
Trial: NCT02025803
Drug: TAS-114/capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1 (dose-escalation phase):~Treatment cycles of TAS-114 and capecitabine orally BID for 14 days followed by 7 days rest until at least one of the discontinuation criteria are met TAS-114 dose starting at 20mg/m2/day with capecitabine dose of 760 mg/m2/day. TAS-114 doses will be escalated for each cohort up to 480mg/m2/day. If MTD is not reached by TAS-114 dose of 480mg/m2/day, the capecitabine dose will be escalated~Part 2 (expansion phase):~TAS-114 and capecitabine MTD established in Part 1 administered BID for 14 days followed by 7-day recovery period (21-day cycle).
Trial: NCT00891163
Drug: Synera™ Topical Patch (70 mg lidocaine/70 mg tetracaine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 minute applicable on antecubital fossa
Trial: NCT00891163
Drug: Placebo Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00863174
Drug: SPARC147709
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPARC147709 injection
Trial: NCT00863174
Drug: Reference147709
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference147709 injection
Trial: NCT01824693
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04958720
Drug: Chemotherapy, anti-targeted agents and immunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy, anti-targeted agents and immunotherapy
Trial: NCT01746940
Drug: Placebo Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Topical Solution
Trial: NCT02700919
Drug: BCT197
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules will be taken orally with fluids over a 5 day period after randomization
Trial: NCT02700919
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules will be taken orally with fluids over a 5 day period after randomization
Trial: NCT00240487
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive inhaled Nitric Oxide at a dose of 10 parts per million (ppm) for a 4 hour study period. Blood gases will be collected once an hour.
Trial: NCT04120233
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo administered orally
Trial: NCT04120233
Drug: MW151, 10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg MW151, 1 x 10mg capsule administered orally
Trial: NCT04120233
Drug: MW151, 20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg MW151, 1 x 20mg capsule administered orally
Trial: NCT04120233
Drug: MW151, 40mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg MW151, 2 x 20mg capsule administered orally
Trial: NCT04120233
Drug: MW151, 80mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg MW151, 1 x 80mg capsule administered orally
Trial: NCT04120233
Drug: MW151, 160mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg MW151, 2 x 80mg capsule administered orally
Trial: NCT00452244
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 40mg/QD po daily every 3 weeks
Trial: NCT01258608
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution for intravenous infusion will be administered as placebo for mapatumumab
Trial: NCT04205630
Drug: SYD985
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYD985 powder for concentrate for solution for infusion
Trial: NCT00587327
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline solution for IV administration. Bolus and infusion for 4 hours.
Trial: NCT01297309
Drug: NPSP558
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will inject NPSP558 individual titration of 25, 50, 75 or 100 μg SC QD into alternating thighs in the morning via a multidose injection pen device.
Trial: NCT00879138
Drug: VA106483
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00024193
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00024193
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04088110
Drug: Aromatase Inhibitors
RxNorm normalized name: Aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigator chose an aromatase inhibitor (either anastrozole, letrozole or exemestane 1 mg/2.5 mg/25 mg), once daily, oral.
Trial: NCT01364389
Drug: AIN457
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg
Trial: NCT01364389
Drug: ACZ885
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg
Trial: NCT01364389
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to AIN457, ACZ885 and prednisone
Trial: NCT05671315
Drug: Nucleos(t)ide analogue
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAs: Dose please follow the approved dosage, once daily, from the first day until when discontinuation is indicated.~NAs Discontinuation Criteria: A total course of treatment is recommended for at least 4 years, and discontinuation may be considered if HBV DNA is below the lower limit of detection, Alanine aminotransferase renormalization, and HBeAg serological conversion, and remain unchanged (test every 6 months) during a consolidation therapy for at least 3 years. However, a prolonged course of treatment may reduce relapse.
Trial: NCT01967472
Drug: Artemether-lumefantrine combination (AL) dispersable
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00334646
Drug: Oral GW679769
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150mg oral, once daily on days 1-3
Trial: NCT00334646
Drug: IV Cyclophosphamide 500-700mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Cyclophosphamide 500-700mg/m2 on day 1 of each cycle
Trial: NCT03223350
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo cream
Trial: NCT03402295
Drug: Bortezomib, cyclophosphamide, thalidomide, dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between two triple combination chemotherapy that include in different new drugs (bortezomibe e talidomida)
Trial: NCT02983019
Drug: Kagocel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigators could prescribe other drugs in frame of routine clinical practice
Trial: NCT01171391
Drug: VA106483
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
Trial: NCT05759416
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo intra-pocket application
Trial: NCT03709355
Drug: Elpida®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elpida® capsules, 20mg
Trial: NCT03709355
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin Film-coated tablets, 250mg
Trial: NCT03709355
Drug: Levonorgestrel+Ethinylestradiol
RxNorm normalized name: levonorgestrel and ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel 150 μg + Ethinylestradiol 30 μg, Film-coated tablets
Trial: NCT02889757
Drug: Acteylcysteine
RxNorm normalized name: Acetylcysteine
DrugBank: Acetylcysteine magnesium (DB14080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: randomized into three arms
Trial: NCT02514629
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02514629
Drug: Metformin + Testosterone Undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02181803
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching oral 2 mg and/or 10 mg MK-8189 tablets, taken QD
Trial: NCT02181803
Drug: Base Monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For Part 2 only: participants need to be on monotherapy with an atypical antipsychotic medication (eg, Olanzapine, Quetiapine, Paliperidone, Asenapine, Iloperidone, Aripirprazole, Lurasidone, Risperidone \[not to exceed daily dose of 6 mg\], or Ziprasidone.) The participant should be on a stable and well tolerated treatment regimen for at least 2 months prior to screening. NOTE: Clozapine is not allowed.
Trial: NCT03824379
Drug: Antidiabetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: insulin or oral hypoglycemics
Trial: NCT03065868
Drug: H. pylori eradication (Amoxaxillin, Lanston, Clarithromycin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori eradication (Triple Therapy) as first line treatment if eradication failure, quadruple therpy will be provided as 2nd line treatment
Trial: NCT01180855
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill nightly for 42 nights.
Trial: NCT03188848
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose subcutaneous injection of placebo to match BPI-3016
Trial: NCT00950066
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of a placebo once a day
Trial: NCT01253187
Drug: EE 0.02 mg/DRSP 3 mg (YAZ, BAY86-5300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group A: Single 1 film-coated tablet (Ethinylestradiol \[EE\] 0.02mg / Drospirenone \[DRSP\] 3mg) taken orally under fasting condition at intervals of at least one menstrual cycle.
Trial: NCT01253187
Drug: EE 0.02 mg/DRSP 3 mg/L-5-MTHF Ca 0.451 mg (EE20/DRSP/L-5-MTHF Ca)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group B: Single 1 film-coated tablet (Ethinylestradiol \[EE\] 0.02mg / Drospirenone \[DRSP\] 3mg / L-5-methyltetrahydrofolate \[L-5-MTHF\] 0.451mg) taken orally under fasting condition at intervals of at least one menstrual cycle.
Trial: NCT01421433
Drug: Tandrilax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tandrilax (caffeine, carisoprodol, sodium diclofenac, paracetamol). Tablets, administered 3 times a day, for 7 consecutive days.
Trial: NCT01253187
Drug: L-5-MTHF 0.451mg (Metafolin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group C: Single 1 coated tablet (L-5-methyltetrahydrofolate \[L-5-MTHF\] 0.451mg) taken orally under fasting condition at intervals of at least one menstrual cycle.
Trial: NCT01421433
Drug: Dolamin Flex
RxNorm normalized name: Ed Flex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolamin Flex (lysine clonixinate and cyclobenzaprine). Tablets, administered 3 times a day, for 7 consecutive days.
Trial: NCT03561090
Drug: IW-3718
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT03561090
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT01268033
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two infusions - at the dose of 375 mg/m² - will be administrered at one week of interval
Trial: NCT03561090
Drug: Standard-dose PPIs QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: background therapy
Trial: NCT04499573
Drug: CD19/CD22 CAR-T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment plan will be based on stratification by the initial leukemia burden.~Patients with low disease burden will receive a lymphodepletion chemotherapy of fludarabine (total dose 120mg/m2) and cyclophosphamide (total dose 750mg/m2) over 5 days.~Patients will high disease burden will receive a lymphodepletion chemotherapy of fludarabine (total dose 120 mg/m2), cyclophosphamide (total dose 750 mg/m2), cytarabine (total dose 900 mg/m2), etoposide (total dose 450 mg/m2), dexamethasone (total dose 30 mg/m2) over 5 days.~Based on interim analysis the following dosing approach will be implemented starting April 2021:~Cohort 1: CD19+ disease, low and high burden: 1st dose - 150k/kg, 2nd dose - 850k/kg Cohort 2: CD19- disease, low and high burden: 1st dose - 500k/kg, 2nd dose - 500k/kg Cohort 3: HSCT+CAR-T: 100k/kg
Trial: NCT02163733
Drug: AZD9291 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9291 tablets: Part A 80mg od, days 1 and 10 only. Part B 80mg od for 12 months.
Trial: NCT05649761
Drug: QL1604 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive QL1604 injection 0.3 mg/kg,1mg/kg, 3mg/kg,10mg/kg, or 200mg intravenous every 2 weeks or every 3 weeks and will be continued until disease progression or unacceptable toxicity.
Trial: NCT01506505
Drug: Cardiovascular Agents
RxNorm normalized name: CARDIOVASCULAR AGENTS,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorthiazide 12.5mg in individual agents or a combination pill